Biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies.
TG Therapeutics, Inc., a dynamic biopharmaceutical company in its commercial stage, is dedicated to advancing innovative treatments for B-cell malignancies and autoimmune diseases. The company focuses on acquiring, developing, and commercializing novel therapeutic solutions that address significant unmet medical needs.
At the core of TG Therapeutics' pipeline are several promising product candidates. Ublituximab, a glycoengineered monoclonal antibody, is being investigated for its potential in treating B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis. Umbralisib, an oral inhibitor targeting PI3K-delta and CK1-epsilon, is another key candidate under development for CLL, marginal zone lymphoma, and follicular lymphoma.
The company is also advancing Cosibelimab, a human monoclonal antibody that binds to programmed death-ligand 1 (PD-L1), disrupting its interactions with PD-1 and B7.1 receptors. Additionally, TG Therapeutics is exploring TG-1701, an orally available Bruton's tyrosine kinase (BTK) inhibitor with selective properties compared to ibrutinib, and TG-1801, a bispecific antibody targeting CD47 and CD19.
In addition to its robust pipeline, TG Therapeutics has licensed preclinical programs targeting BET, interleukin-1 receptor associated kinase-4 (IRAK-4), and glucocorticoid-induced TNFR-related protein (GITR). The company maintains strategic collaborations with leading biopharmaceutical entities like Checkpoint Therapeutics, Jiangsu Hengrui Medicine, Novimmune, Ligand Pharmaceuticals, and Jubilant Biosys, as well as strategic alliances with LFB Biotechnologies, GTC Biotherapeutics, Ildong Pharmaceutical, and Rhizen Pharmaceuticals. Founded in 1993 and headquartered in New York, New York, TG Therapeutics continues to drive innovation and expand its footprint in the biopharmaceutical landscape.